BRIEF-Syros announces preclinical data on SY-1425
* Syros presents data at EHA supporting potential of SY-1425, its first-in-class selective RARα agonist, in genomically defined AML and MDS patients
May 9 Aurinia Pharmaceuticals Inc:
* Pharma industry veteran Dr. George Milne joins Aurinia’s board of directors Source text for Eikon: Further company coverage:
June 23 A handful of drugmakers are taking their first steps toward developing marijuana-based painkillers, alternatives to opioids that have led to widespread abuse and caused the U.S. health regulator to ask for a withdrawal of a popular drug this month.